BPC-157 and TB-500 are the two most extensively studied tissue repair peptides in the preclinical research literature. Both appear in a substantial body of published studies, both are categorized as tissue repair compounds, and both are frequently discussed in the same research contexts. Yet they are molecularly distinct compounds with different mechanisms of action, different primary research applications, and different considerations for laboratory use.
This comparison examines the two compounds side by side — their molecular profiles, documented research applications, mechanisms, and what researchers should consider when deciding which compound is appropriate for a given experimental context.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Full name | Body Protection Compound 157 | Thymosin Beta-4 synthetic analogue |
| Amino acids | 15 | 43 |
| Molecular weight | 1,419.55 g/mol | 4,963.44 g/mol |
| CAS number | 137525-51-0 | 77591-33-4 |
| Origin | Gastric juice protein fragment | Thymus-derived protein |
| Primary mechanism | Growth factor signaling, NO modulation | Actin sequestration, cell migration |
| Primary research areas | Tissue repair, GI, neurology | Musculoskeletal, cardiac, angiogenesis |
| Water solubility | Yes | Yes |
| Storage (lyophilized) | -20°C | -20°C |
| Purity (Official Peptides) | >99% HPLC | >99% HPLC |
BPC-157 (GEPPPGKPADDAGLV) is a 15-amino acid synthetic peptide derived from a partial sequence of human gastric juice protein. With a molecular weight of 1,419.55 g/mol, it is relatively small compared to most research peptides — a characteristic that contributes to its documented stability and water solubility.
Unlike TB-500, BPC-157 has no known naturally occurring endogenous form — it is a synthetic compound designed to replicate and isolate specific biological activities observed in gastric juice protein. This makes it a purely synthetic research tool with no direct natural analogue.
TB-500 is the synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in virtually all human and animal cells. With a molecular weight of 4,963.44 g/mol, TB-500 is significantly larger than BPC-157 — a difference that has practical implications for synthesis complexity, storage handling, and reconstitution.
Thymosin Beta-4 is one of the most abundant intracellular peptides in the body, playing fundamental roles in actin regulation and cellular homeostasis. TB-500 represents the key functional domain of this protein — the actin-binding sequence — synthesized for research applications.
BPC-157’s primary research-documented mechanisms involve interactions with growth factor signaling pathways and the nitric oxide (NO) system. Key mechanistic findings from published research include:
VEGF upregulation — Multiple studies have documented BPC-157’s apparent ability to increase VEGF expression in tissue repair models, promoting angiogenesis in healing tissue.
NO system modulation — Research has examined BPC-157’s interactions with nitric oxide synthase (NOS) activity, with studies reporting both protective and modulatory effects on NO-mediated signaling in gastrointestinal and vascular models.
Growth factor receptor interaction — Studies have examined BPC-157’s effects on EGF and FGF receptor signaling, with research suggesting interactions that may contribute to its observed effects on cell proliferation and tissue repair.
FAK and paxillin interaction — Research has documented BPC-157’s interactions with focal adhesion kinase (FAK) and paxillin — proteins involved in cell adhesion and migration signaling — which may contribute to its effects on cell motility in repair models.
TB-500’s primary mechanism is fundamentally different: it functions as a G-actin sequestering peptide, regulating the dynamic equilibrium between monomeric and filamentous actin.
Actin sequestration — TB-500 binds G-actin (monomeric actin), modulating the availability of actin monomer for polymerization into F-actin filaments. This regulation of actin dynamics underlies the compound’s observed effects on cell migration and morphology.
Cell migration promotion — By modulating actin dynamics, TB-500 promotes cell migration — a fundamental requirement for wound closure, immune cell recruitment, and tissue regeneration. Studies have documented increased migration rates in multiple cell types including endothelial cells, keratinocytes, and stem cells.
Cardiac progenitor activation — Seminal research has documented TB-500’s unique ability to activate epicardium-derived cardiac progenitor cells in adult cardiac tissue — a mechanism not documented for BPC-157 and of particular interest to cardiac biology researchers.
ILK pathway interaction — TB-500 has been shown to interact with integrin-linked kinase (ILK) signaling — a pathway involved in cell survival, proliferation, and migration — which may contribute to its observed effects in cardiac and vascular research models.
Gastrointestinal research — BPC-157’s origins in gastric juice protein make it the more extensively studied compound in GI models. Research examining gastric ulcer healing, intestinal permeability, inflammatory bowel disease models, and gut-brain axis interactions has primarily used BPC-157 rather than TB-500.
Neurological models — BPC-157 has a more substantial literature base in neurological research than TB-500. Studies examining traumatic brain injury, spinal cord injury, peripheral nerve damage, and interactions with dopaminergic and serotonergic systems have predominantly used BPC-157.
Tendon-to-bone healing — While both compounds have been studied in tendon research, BPC-157 has a particularly extensive literature in tendon-to-bone healing models — the specific interface between tendon and bone attachment points.
Cardiac biology — TB-500 has a significantly stronger research base in cardiac applications than BPC-157. The discovery of Thymosin Beta-4’s role in cardiac progenitor cell activation has generated substantial research interest specifically in TB-500, with multiple groups studying its interactions with cardiac repair pathways.
Actin-dependent cell migration — Research examining the specific mechanisms of cell migration via actin dynamics is predominantly TB-500 territory. Researchers studying cytoskeletal biology, endothelial cell migration, and actin-dependent processes will find a more directly applicable literature base with TB-500.
Systemic inflammation models — TB-500 has been more extensively studied in systemic inflammation contexts — models examining whole-organism inflammatory responses rather than tissue-specific inflammation.
Both compounds have been studied extensively in:
– General musculoskeletal repair (muscle, bone, ligament)
– Anti-inflammatory mechanisms
– Angiogenesis and vascularization
– Wound healing models
In these overlapping areas, many research groups study both compounds — either in parallel experiments to compare effects, or in combination to examine potential interactions.
A significant and growing body of research examines BPC-157 and TB-500 in combination rather than as alternatives. The rationale for combined study is mechanistic: the two compounds act through different primary pathways, suggesting the possibility of complementary or synergistic interactions in tissue repair contexts.
Research examining combined BPC-157 and TB-500 administration in repair models has generally reported outcomes consistent with both compounds’ individual documented effects — though the specific interactions between their respective pathways remain an active area of investigation.
For researchers designing experiments in tissue repair models, the decision to study one or both compounds should be guided by the specific pathways and endpoints of interest:
Both compounds are supplied as lyophilized powder and reconstituted with sterile bacteriostatic water. Both should be stored at -20°C in lyophilized form.
The key practical difference: TB-500’s larger molecular weight makes it more susceptible to degradation from repeated freeze-thaw cycles. Researchers using TB-500 should aliquot reconstituted solutions more diligently than with BPC-157 — the cost of degradation is higher given the compound’s greater molecular complexity.
Both compounds should be sourced at >99% purity by HPLC for research applications. For TB-500, high purity is particularly critical given its molecular size — at lower purities, a greater absolute mass of contaminating material is present relative to smaller peptides at equivalent purity percentages.
Both BPC-157 and TB-500 are available from Official Peptides at >99% purity, with independent third-party HPLC verification and published certificates of analysis for every production batch. Researchers requiring both compounds for parallel or combined experiments can source from a single verified supplier — simplifying procurement and ensuring consistent quality standards across both compounds.
Can BPC-157 and TB-500 be used together in research?
Yes — many research groups study both compounds simultaneously in tissue repair models. The compounds operate through distinct primary mechanisms, making combined study of potential scientific interest. Researchers should design experiments carefully to isolate the effects of each compound and any potential interactions.
Which compound has more published research?
BPC-157 has a slightly larger overall literature base, with particularly extensive documentation in GI and neurological models. TB-500 has a stronger specific literature in cardiac biology and actin-dependent cell migration. Both have substantial bodies of preclinical research supporting their use as tool compounds in tissue repair research.
Are BPC-157 and TB-500 structurally related?
No. Despite their shared categorization as tissue repair peptides, BPC-157 and TB-500 are structurally unrelated compounds with distinct amino acid sequences, molecular weights, and mechanisms of action. Their shared research context reflects their overlapping functional effects in tissue repair models rather than any structural relationship.
Which compound is more stable in storage?
BPC-157’s smaller molecular weight (1,419.55 g/mol vs 4,963.44 g/mol for TB-500) generally confers greater stability in storage and handling. Both should be stored at -20°C in lyophilized form, but TB-500 requires more careful aliquoting of reconstituted solutions to avoid degradation from freeze-thaw cycling.
Where can I source both BPC-157 and TB-500 for research?
Official Peptides supplies both BPC-157 and TB-500 at >99% purity with independent third-party verification and batch-specific COA documentation. Both are available in multiple vial sizes to suit different research scales.
BPC-157 and TB-500 are complementary rather than competing research compounds. Their distinct mechanisms — BPC-157 via growth factor and NO signaling, TB-500 via actin dynamics and cell migration — mean that they address different aspects of the tissue repair process and are often most informative when studied together.
For researchers making sourcing decisions, the choice between BPC-157 and TB-500 should be guided by the specific pathways and endpoints of interest. For many tissue repair research programs, both compounds merit inclusion in the experimental toolkit.
Official Peptides supplies both compounds at >99% purity with independent third-party verification.
→ View BPC-157 product page
→ View TB-500 product page
This content is authored by Priya Anand, Research Scientist specialising in endocrinology and peptide pharmacology. All information is provided for research reference purposes only. BPC-157 and TB-500 are not approved for human use and are not intended for diagnostic or therapeutic purposes. For in vitro laboratory research use only.
All content is provided for research reference purposes only. For in vitro laboratory research use only.